As such, neutralization of BLyS/BAFF with Belimumab restored sensitivity of BLyS/BAFF prone chronic lymphoid leukemia cells to Rituximab, supporting there is a benefit in combining anti-CD20 and anti-BLyS/BAFF in certain circumstances [44]. This evidence concerns the gene TNFSF13B and lymphoid leukemia.